Levetiracetam Hikma

Levetiracetam, the active ingredient in Levetiracetam Hikma, is an anticonvulsant presented as an injectable solution for intravenous use. It treats partial‑onset seizures, myoclonic seizures, and primary generalized tonic‑clonic seizures in patients who require rapid seizure control. The product is approved in the European Union for use in both adult and pediatric populations.

GNH USA supplies Levetiracetam Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice and provides temperature‑controlled logistics for injectable medicines.

Levetiracetam is an antiepileptic medication that modulates synaptic transmission to reduce abnormal neuronal firing, providing effective control for several seizure types across diverse patient populations. - Partial‑onset seizures: reduces frequency and severity of focal seizures, improving patient quality of life. - Myoclonic seizures: controls sudden brief muscle jerks, decreasing episode occurrence and associated injury risk. - Primary generalized tonic‑clonic seizures: prevents widespread convulsive episodes, aiding seizure control in generalized epilepsy. - Adjunct therapy: can be combined with other antiepileptic drugs to enhance overall seizure management.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness or reduced energy. - Dizziness: light‑headed sensation, especially when standing quickly. - Headache: mild to moderate pain in the head region. - Nasopharyngitis: symptoms of an upper respiratory tract infection.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood changes: depression, anxiety, or suicidal thoughts. - Hematologic abnormalities: low blood cell counts such as neutropenia. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating therapy, clinicians should consider patient‑specific factors and monitor for potential risks. - Renal impairment: assess kidney function and adjust dosage if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Pregnancy: use only if potential benefits justify the risk to the fetus. - Concomitant CNS depressants: observe for additive sedation or respiratory depression. - Psychiatric history: watch for emergence or worsening of mood disturbances. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam may interact with other medications, requiring careful management.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma concentrations. - Phenytoin: can decrease levetiracetam efficacy. - Phenobarbital: may lower levetiracetam levels.

Moderate Interactions (Monitor Closely): - Alcohol: may increase central nervous system depression. - Other antiepileptic drugs: dose adjustments may be needed. - Renal excretion inhibitors: monitor renal function and drug levels.